SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096213
Filing Date
2024-08-13
Accepted
2024-08-13 16:10:54
Documents
77
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kzr-20240630.htm   iXBRL 10-Q 2147607
2 EX-10.1 kzr-ex10_1.htm EX-10.1 28478
3 EX-31.1 kzr-ex31_1.htm EX-31.1 16371
4 EX-31.2 kzr-ex31_2.htm EX-31.2 16336
5 EX-32.1 kzr-ex32_1.htm EX-32.1 9702
6 GRAPHIC img40159629_0.jpg GRAPHIC 81338
  Complete submission text file 0000950170-24-096213.txt   9218098

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240630.xsd EX-101.SCH 1182425
79 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240630_htm.xml XML 1667013
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38542 | Film No.: 241201533
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)